Internal Medicine
Mounjaro vs Wegovy vs Ozempic: Differences, Effectiveness, Side Effects, and Which Suits Whom
Reviewed by the JordanMedHub Medical Editorial Team · 8/29/2026
Quick Answer
A clear, side-by-side look at what separates these three medications — active ingredient, approved use, and how to think about the choice.
In this article
These three medications are often mentioned in the same breath, but they split into two different active ingredients and three different approved uses. Here's how to keep them straight.
The Core Distinction
- Ozempic and Wegovy both contain semaglutide — Ozempic is approved for type 2 diabetes, Wegovy for chronic weight management.
- Mounjaro contains tirzepatide, a different active ingredient that acts on two hormone receptors (GLP-1 and GIP) instead of one, authorised for type 2 diabetes and — in the EU — also for weight management (in the US the weight-management version has its own brand).
Mechanism of Action
Semaglutide (Ozempic/Wegovy) activates the GLP-1 receptor alone. Tirzepatide (Mounjaro) activates both GLP-1 and GIP receptors.
Side-by-Side Comparison
| Ozempic | Wegovy | Mounjaro | |
|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Tirzepatide |
| Hormone receptors | GLP-1 | GLP-1 | GLP-1 and GIP |
| EU-authorised for | Type 2 diabetes in adults | Weight management (adults; adolescents 12+) | Type 2 diabetes and weight management |
| Usual form | Weekly injection | Weekly injection (a daily tablet for adults is also listed by the EMA) | Weekly injection |
| Dose increase | Gradual, from a low starting dose | Gradual over about 16 weeks | Gradual, from a low starting dose |
| EU authorisation | 2018 | — | 2022 |
Ozempic is not authorised for weight loss, even though semaglutide is the same molecule as Wegovy; when a doctor prescribes Ozempic for weight, that is off-label use.
What the Head-to-Head Trial Found
In SURMOUNT-5, 751 adults with obesity but without diabetes took the maximum tolerated dose of tirzepatide or semaglutide for 72 weeks. Average weight change was −20.2% with tirzepatide and −13.7% with semaglutide (a 6.5-point difference). Most side effects in both groups were digestive and mild to moderate. Two cautions: it was a single open-label trial in people without diabetes, and averages hide wide individual variation.
Which One Fits Which Situation? (Questions for Your Doctor)
| Your situation | What tends to matter |
|---|---|
| Type 2 diabetes is the main issue | Ozempic and Mounjaro are authorised for diabetes; your doctor also weighs kidney and heart health and other medicines |
| Obesity without diabetes | Wegovy and, in some markets, Mounjaro are labeled for weight management; local registration and availability decide what is actually an option |
| Digestive side effects worry you | All three cause nausea, vomiting, diarrhea or constipation, mainly during dose increases — ask about the pace of dose steps |
| You might become pregnant | Mounjaro: the NHS advises stopping at least four weeks before trying to conceive and extra barrier contraception after starting and each dose increase — ask for guidance on any of them |
| Cost or supply is a constraint | Prices and pharmacy stock change; JordanMedHub has no verified data on them |
Fake Products Are a Bigger Risk Than the Choice Between Them
Jordan's JFDA has warned that oral "Mounjaro" pills sold via social media are counterfeit and unregistered, and that selling medicines online is prohibited. That warning is specific to Mounjaro; treat any online offer for Wegovy or Ozempic with the same caution. Read our complete GLP-1 guide and the Mounjaro guide before you decide.
Related Reading
Wegovy guide · Ozempic guide · switching or stopping · bariatric surgery vs GLP-1 · BMI calculator · endocrinology
Emerging trend — evidence still developing
A completed head-to-head randomized controlled trial (SURMOUNT-5) found that tirzepatide-based medication produced significantly greater average weight loss than semaglutide-based medication over 72 weeks — though individual responses vary considerably, and this is not a reason to choose one over another without a doctor's input.
Effectiveness Isn't the Only Factor
Cost, insurance or national health system coverage, local availability, side-effect tolerance, and whether you're primarily managing diabetes or pursuing weight management all factor into which medication — if any — a doctor might recommend. There is no single "best" option that applies to everyone.
Side Effects
All three share a broadly similar side-effect profile (mainly digestive), covered in detail in our side effects and risks guide.
How to Decide
This isn't a decision to make from a comparison article alone. A doctor will consider your diagnosis (diabetes vs. obesity without diabetes), other health conditions, other medications, and what's realistically available to you. Our eligibility guide covers the general criteria doctors use as a starting point for that conversation.
Sources
- Mounjaro — European Medicines Agency (EPAR)
- Wegovy — European Medicines Agency (EPAR)
- Ozempic — European Medicines Agency (EPAR)
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) — PubMed
- Tirzepatide (Mounjaro) — NHS medicines
Disclaimer
This comparison is for general education only and does not recommend any specific medication. Only a doctor with full knowledge of your health history can determine which option, if any, is appropriate.
Frequently Asked Questions
Which is better, Mounjaro or Ozempic?
There's no single answer — it depends on your diagnosis, health history, goals, and what's available to you. Research suggests differences in average effectiveness, but individual results vary and a doctor's assessment matters more than a general comparison.
Can I switch from Ozempic to Mounjaro or Wegovy?
Switching between GLP-1 medications is something doctors do consider in some cases, but it should always be planned and supervised by a doctor, not done independently.
Are all three equally available in Jordan and the Gulf?
Availability, registration status, and pricing can vary by country and even by pharmacy. Ask a licensed doctor or pharmacist about what's currently available where you are.
Is Ozempic the same as Wegovy?
They contain the same active ingredient, semaglutide, but are authorised for different uses: Ozempic for type 2 diabetes and Wegovy for weight management. Ozempic is not authorised for weight loss; prescribing it for that purpose is off-label.
Did Mounjaro beat semaglutide in a head-to-head trial?
In SURMOUNT-5 (751 adults with obesity, no diabetes, 72 weeks), average weight change was −20.2% with tirzepatide and −13.7% with semaglutide. Results are averages from one open-label trial and individual outcomes vary.
Are the side effects of Mounjaro, Wegovy and Ozempic different?
They are broadly similar and mainly digestive — nausea, vomiting, diarrhea, constipation and stomach pain — especially while the dose is being increased. Severe or persistent stomach pain, signs of an allergic reaction or very low blood sugar need urgent medical help.
Written by JordanMedHub Medical Editorial Team
Updated
Need to speak with a specialist?
Find a doctor near you to discuss your symptoms and treatment options.
Find a doctorRelated articles
Mounjaro (Tirzepatide): How It Works, Uses, Side Effects, Safety, and Jordan Warning
Wegovy (Semaglutide): The Weight-Management-Specific GLP-1 Injection
Ozempic (Semaglutide): What It's Approved For, and the Weight-Loss Question
Who Is a Candidate for GLP-1 Weight-Loss Injections (and Who Isn't)
Why Am I Not Losing Weight on GLP-1 Injections? Understanding Plateaus